Compare PRAX & NVTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | NVTS |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.3B |
| IPO Year | 2020 | 2020 |
| Metric | PRAX | NVTS |
|---|---|---|
| Price | $263.71 | $23.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $572.13 | $6.68 |
| AVG Volume (30 Days) | 427.5K | ★ 33.8M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $45,916,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7,758.26 | $71.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.25 | $5.44 |
| 52 Week High | $366.52 | $34.17 |
| Indicator | PRAX | NVTS |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 51.45 |
| Support Level | $157.29 | $23.59 |
| Resistance Level | $342.62 | $34.00 |
| Average True Range (ATR) | 21.68 | 3.07 |
| MACD | -6.71 | -1.00 |
| Stochastic Oscillator | 20.77 | 25.68 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.